The Popularity of “Special Pop”: Antibiotics Incentives and PDUFA V
This article was originally published in RPM Report
The Infectious Diseases Society of America’s “Special Population” approval mechanism has proponents within FDA and industry. That makes it look like a good balancing proposal to complement the market incentives for anti-infectives being pushed under the GAIN Act add-on to PDUFA V. There is one big hurdle, however: GAIN’s major legislative proponent, Rep. Phil Gingrey (R-GA) does not like the limitations on use post-approval.
You may also be interested in...
FDA Prepares For LPAD: Orphan Drug Approvals Are Model
One of the bedrock consensus issues throughout the drafting of the “21st Century Cures” legislation has been that the bill should create a pathway for approval of new antibacterials for limited populations – known as LPAD. But what would it actually do?
Astellas Antifungal Nabs 12-Year Exclusivity: QIDP+Orphan Combos Are Rare
Cresemba (isavuconazonium), the first antifungal approved with added exclusivity award for Qualified Infectious Disease Products, also becomes first product to receive both QIDP and Orphan Drug exclusivity.
Astellas Antifungal Isavuconazole In Line For 12-Year Exclusivity: QIDP+Orphan Combos Are Rare
Astellas Pharma’s isavuconazole should soon become the first antifungal therapy approved with the added exclusivity award for Qualified Infectious Disease Products under the GAIN Act. It will also be the first product to receive both QIDP and Orphan Drug exclusivity – a combination that probably won’t happen often.